Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
Lung Disease
About this trial
This is an interventional treatment trial for Lung Disease focused on measuring moderate to severe allergic asthma
Eligibility Criteria
Inclusion Criteria: On medium to high dose inhaled corticosteroids either with or without a long acting beta agonist Baseline IgE 30-700 IU/mL Exhaled nitric oxide greater than 13 ppb Positive skin test to at least one of the following perennial allergens: cat, dog, dust mite, cockroach Stable asthma at the time of enrollment Exclusion Criteria: Concurrent diseases/conditions, history of other diseases/conditions, with clinically significant uncontrolled systemic disease or a history of such disease (eg, infection, hematological, renal, hepatic, coronary heart disease or other cardiovascular disease, endocrinological, or gastrointestinal disease) within previous 3 months Upper or lower respiratory tract infection within 6 weeks of screening visit Elevated IgE level other than atopy Known sensitivity to Xolair < 3 months of stable immunotherapy Smokers Pregnant/nursing women Women of childbearing potential who are not practicing medically approved contraceptive methods (eg, oral, subcutaneous, mechanical, or surgical contraception) including abstinence Patients who currently hav diagnosed cancer, are currently being investigated for possible cancer or who have any history of cancer Known sensitivity to study drug or class of study drugs Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study Use of any other investigational agent in the last 30 days.
Sites / Locations
- Creighton University Division of Allergy & Immunology
- Albany Medical College
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo
Xolair
Saline placebo
Xolair treatment